Abstract
A range of experimental and clinical data suggests strongly (i) that metastatic progression in carcinomas is accompanied (maybe even preceded) by upregulation of functional voltage-gated sodium channels (VGSCs) and (ii) that VGSC activity enhances cancer cell invasiveness. First, this review outlines the available in vitro and in vivo evidence for the VGSC expression and its proposed pathophysiological role. Second, we question the mechanism(s) whereby VGSC activity can induce such a cancer-promoting effect. We advance the hypothesis that it is the hypoxia-sensitive persistent component of the VGSC current (INaP) that is central to the phenomenon. Indeed, blockers of INaP are very effective in suppressing cancer cell invasiveness in vitro. Based upon these data, UK and international patent applications have been filed which describe the use of INaP blockers, like ranolazine (“Ranexa”) and riluzole (“Rilutex”), as anti-metastatic agents. Importantly, since these drugs are already in clinical use, against conditions like cardiac angina and amyotrophic lateral scelerosis, there are no issues of dosage, unacceptable side effects or long-term use. Thus, INaP blockers have the potential to turn cancer into a chronic condition.
Keywords: Hypoxia, metastasis, persistent current, ranolazine, riluzole, voltage-gated sodium channel
Recent Patents on Anti-Cancer Drug Discovery
Title:Persistent Current Blockers of Voltage-Gated Sodium Channels: A Clinical Opportunity for Controlling Metastatic Disease
Volume: 8 Issue: 1
Author(s): Mustafa B.A. Djamgoz and Rustem Onkal
Affiliation:
Keywords: Hypoxia, metastasis, persistent current, ranolazine, riluzole, voltage-gated sodium channel
Abstract: A range of experimental and clinical data suggests strongly (i) that metastatic progression in carcinomas is accompanied (maybe even preceded) by upregulation of functional voltage-gated sodium channels (VGSCs) and (ii) that VGSC activity enhances cancer cell invasiveness. First, this review outlines the available in vitro and in vivo evidence for the VGSC expression and its proposed pathophysiological role. Second, we question the mechanism(s) whereby VGSC activity can induce such a cancer-promoting effect. We advance the hypothesis that it is the hypoxia-sensitive persistent component of the VGSC current (INaP) that is central to the phenomenon. Indeed, blockers of INaP are very effective in suppressing cancer cell invasiveness in vitro. Based upon these data, UK and international patent applications have been filed which describe the use of INaP blockers, like ranolazine (“Ranexa”) and riluzole (“Rilutex”), as anti-metastatic agents. Importantly, since these drugs are already in clinical use, against conditions like cardiac angina and amyotrophic lateral scelerosis, there are no issues of dosage, unacceptable side effects or long-term use. Thus, INaP blockers have the potential to turn cancer into a chronic condition.
Export Options
About this article
Cite this article as:
B.A. Djamgoz Mustafa and Onkal Rustem, Persistent Current Blockers of Voltage-Gated Sodium Channels: A Clinical Opportunity for Controlling Metastatic Disease, Recent Patents on Anti-Cancer Drug Discovery 2013; 8 (1) . https://dx.doi.org/10.2174/1574892811308010066
DOI https://dx.doi.org/10.2174/1574892811308010066 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immunomodulatory Activity of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Bacterial Adaptation and Infection
Inflammation & Allergy - Drug Targets (Discontinued) Carfilzomib: A Tale of a Heartbreaking Moment: Case Report and Concise Review of the Literature
Cardiovascular & Hematological Disorders-Drug Targets Potential Role of IL-18 in the Immunopathogenesis of AIDS, HIVAssociated Lipodystrophy and Related Clinical Conditions
Current HIV Research Overlap Syndrome of Chronic Obstructive Pulmonary Disease and Obstructive Sleep Apnea: A Two-Faced Janus
Current Respiratory Medicine Reviews Rewiring the Heart: Stem Cell Therapy to Restore Normal Cardiac Excitability and Conduction
Current Stem Cell Research & Therapy Human Parvovirus B19: An Infectious Agent with the Potential to Induce and Trigger Rheumatic Disease
Current Rheumatology Reviews Current Therapeutic Concepts in Peripartum Cardiomyopathy
Current Pharmaceutical Design Crystallization and Preliminary X-Ray Analysis of the Highly Thermostable Sweet Protein Mabinlin II
Protein & Peptide Letters Nitric Oxide and the Regulation of Apoptosis in Tumour Cells
Current Pharmaceutical Design Animal Models of Narcolepsy
CNS & Neurological Disorders - Drug Targets Direct Renin Inhibition: Promising Treatment in Renoprotection?
Recent Patents on Cardiovascular Drug Discovery Recent Advances in Small Animal Cardiac Magnetic Resonance Imaging
Current Cardiology Reviews Hypertension and Endothelial Dysfunction: Therapeutic Approach
Current Vascular Pharmacology Serotonin Reuptake Inhibitors and Cardiovascular Disease
Vascular Disease Prevention (Discontinued) Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets
Current Drug Targets New Frontiers in Regenerative Medicine in Cardiology: The Potential of Wharton’s Jelly Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Role of PPAR in Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Do Advanced Glycation End Products (AGEs) Contribute to the Comorbidities of Polycystic Ovary Syndrome (PCOS)?
Current Pharmaceutical Design Stem Cells and Translational Medicine: From Research to Clinical Procedures
Current Tissue Engineering (Discontinued)